WASHINGTON — President Biden’s presumed pick to lead the National Institutes of Health, Monica Bertagnolli, will face a slew of questions on the multibillion-dollar agency’s spending and oversight in her upcoming confirmation battle.
This week, though, she won’t face what otherwise would have been Congress’s first round. A source close to the top cancer official, who announced her own cancer diagnosis last December, said she had to drop out of a scheduled Senate Appropriations Committee hearing Thursday because of previously scheduled routine cancer treatment, though she remains healthy.
The National Cancer Institute’s second-in-command, Douglas Lowy, will testify instead, alongside acting NIH director Lawrence Tabak and other senior NIH officials.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
